WEP
Warwick
Evans
Publishing

Transactions on Materials, Biotechnology and Life Sciences
ISSN: 2960-1932, eISSN: 2960-2319 | Volume 3
BLSME 2024

To What Extent does CRISPR/Cas9 Truly Elevate Target Efficiency and Revolutionize Drug Discovery?

Leyao Gao *

Department of Biomedical Science, King's College London, London, United Kingdom

* Corresponding Author Email: leyao.gao@kcl.ac.uk

Abstract. The emergence of the CRISPR/Cas9 system has ushered in a new era of genetic editing with vast implications for both therapeutic interventions and drug discovery. This essay explores the extent to which CRISPR/Cas9 elevates target efficiency and revolutionizes drug discovery. While this technology offers unprecedented efficiency, precision, and programmability in genome editing, concerns about off-target effects have arisen. The essay discusses the transformative impact of CRISPR/Cas9 in drug discovery, particularly in cancer research and combating antimicrobial resistance. It also highlights strategies for detecting and mitigating off-target effects, such as in silico prediction tools, experimental methods, and precision-enhancing techniques. Ultimately, CRISPR/Cas9's potential is undeniable, but its full realization depends on ongoing research and refinement to optimize specificity and revolutionize the field of drug discovery.

Keywords: bioinformatics; CRISPR/Cas9; drug discovery; target efficiency; gene editing; cancer research; antimicrobial resistance; in silico prediction tools.

1. Introduction

The world of genetic editing has undergone a revolutionary shift with the introduction of the CRISPR)/Cas9 system (clustered regularly interspaced short palindromic repeats) [1]. This breakthrough technology has propelled gene editing into a new era, characterized by efficiency, precision, and programmability. Such advancements hold immense potential for clinical trials and translational studies, encompassing both non-genetic and genetic disorders [2]. Nonetheless, as this transformative tool continues to gain momentum, concerns surrounding its off-target effects have emerged as a critical consideration. Off-target effects denote unintended and potentially harmful alterations in the genome, casting a shadow over the otherwise promising prospects of CRISPR/Cas9 applications [3].

The traditional landscape of genome editing was reshaped by the advert of CRISPR/Cas9, which superseded the complexities and limitations of earlier methodologies such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) [2]. CRISPR/Cas9 functions through the formation of ribonucleoprotein complexes, comprising the Cas9 enzyme and a single guide RNA (sgRNA), thereby offering a precise mechanism for inducing DNA cleavages at specific genomic loci. This approach eliminates the need for laborious and expensive protein engineering and has revolutionized biotechnology with its ease of use and cost-effectiveness [4, 5].

Despite the immense promise, the potency of CRISPR/Cas9 is accompanied by concerns surrounding off-target effects. While in silico tools aid in predicting potential off-target sites, the off-target impact extends beyond just sgRNA-dependent occurrences, necessitating unbiased experimental detection and validation [3]. These challenges have prompted a dynamic field of research, culminating in an array of methods to assess and manage off-target effects. These advances are essential for realizing the full potential of CRISPR/Cas9 in gene therapy [6].

In parallel, CRISPR/Cas9 is also reshaping drug discovery, a dimension that could prove as significant as its therapeutic applications [2]. By deliberately activating or inhibiting genes using CRISPR/Cas9, researchers can unravel the intricate web of genes and proteins responsible for diseases, laying the foundation for drug target identification [1]. This technique also facilitates the creation of disease-specific cellular and animal models, enabling researchers to validate the efficacy and safety of potential drugs with greater accuracy [5].

Knock-out experiments utilizing CRISPR/Cas9 are at the forefront of drug discovery, aiding in identifying genes associated with drug resistance. The technology's ability to precisely and consistently knock out specific genes enhances the reliability of large-scale gene-function studies. Moreover, the ease of uncovering subtle interactions among genes and proteins provides a sophisticated understanding of disease pathways, paving the way for more nuanced drug development approaches [2].

As CRISPR/Cas9 catalyzes advances in both gene editing and drug discovery, the question arises: to what extent does CRISPR/Cas9 truly elevate target efficiency and revolutionize drug discovery? This essay seeks to navigate this query, probing the multifaceted dimensions of CRISPR/Cas9's impact on target precision and drug development. By delving into its implications, challenges, and potential, the exploration endeavors to paint a comprehensive picture of CRISPR/Cas9's role in advancing target efficiency and transforming the landscape of drug discovery.

2. Method & Result & Discussion

2.1. Advancement in Drug Discovery

The field of drug discovery has experienced a profound transformation with the introduction of CRISPR-Cas9. This pioneering instrument has fundamentally altered the paradigm for identifying prospective therapeutic targets and devising novel treatment modalities, with particular emphasis on its applications in cancer research through CRISPR-Cas9 screens, as well as its application in addressing antiviral, antimicrobial, and AIDS-related research endeavors [1, 2].

2.2. CRISPR-Cas9 Application in AIDS, antiviral and antimicrobial research

The extensive and indiscriminate use of antibiotics has led to a significant release of these compounds into the environment over time. Consequently, this misuse has spurred the emergence of widespread resistance to antibiotics. The root causes of this antimicrobial resistance (AMR) dilemma include the reduced production of new and innovative antibiotic drugs, as well as the absence of novel classes of antibiotics for treatment [1, 7]. This scarcity of therapeutic options has pushed scientists to explore alternative strategies to address antibiotic-resistant pathogens. One such innovative approach involves leveraging the encoding phage of CRISPR-Cas9 and Cas-3. These entities have been harnessed as a potential solution to combat the threat from AMR [2].

By precisely targeting the resistance-associated genes, the CRISPR-Cas13a system not only aims to curb the proliferation of AMR genes, but also execute gene-specific bacterial elimination [8]. A notable finding by Abudayyeh and colleagues. indicates the system can trigger the cleavage of single-stranded RNA, results in halting the growth of bacteria. This mechanism serves as immune responses, preventing the invasion of bacteria by targeting their nucleic acids. This defense mechanism involves incorporating short sequences known as spacers, derived from foreign genetic material like DNA or RNA, into the bacterial genome at CRISPR loci. Subsequently, the Cas protein recognizes these spacers, enabling the identification and destruction of invading nucleic acids that share similar sequences [9].

The operation of the system could be succinctly elucidated through three principal stages: adaptation, expression, and interference. During expression phase, pre-crRNA is transcribed with the assistance of RNA polymerase. Subsequently, this precursor RNA undergoes cleavage by endoribonucleases, resulting in the formation of smaller crRNA units. Ultimately, these crRNA molecules engage in base-pairing interactions with foreign genetic material, which consequently cleaves nucleic acid complex. Moreover, certain bacterial species like streptococcus, have evolved an adaptive immune mechanism against viral invaders by harnessing the CRISPR/Cas9 system, as depicted in Figure 1.

These advancements hold the potential to combat resistance and sustain the antimicrobial efficacy of antibiotic drugs [8, 9].



Figure 1. The bacterial CRISPR-Cas9 systems function as an adaptive immune defense mechanism in response to viral intrusions.

In the realm of antiviral therapies, the significance of nucleic acid in the assembly of virus particles and their gene-specific degradation is highlighted. Recent times have seen the development of sequence-specific endonucleases, with CRISPR-Cas9 emerging as the preferred choice due to its feasibility, versatility and specificity during viruses targeting. The process involves the fusion of two small RNAs: tracrRNA and crRNA, producing a single guide RNA (sgRNA), in which then designed based on the targeted viral genome sequence and incorporated into a viral vector or expression plasmid or. Afterward, these constructs are expressed through a plasmid-based transfection process [2, 5]. To gauge efficacy, mutations around the target virus are assessed using endonuclease cleavage assays. Consequently, the potential of CRISPR-Cas9 technology as the exceptional antimicrobial and antiviral therapy for numerous chronic infections is underscored, with specific roles elaborated in tables for reference [7].

In the realm of addressing acquired immunodeficiency syndrome (AIDS), a formidable global health challenge berefts of curative drugs, diverse strategies have been explored to curtail disease progression. Two prominent strategies revolve around curbing HIV replication or achieving functional cures and eliminating the viral traces in infected cells, refers to sterilizing cures [4,7]. However, latent viral reservoirs, harboring dormant infected cells, pose a substantial hurdle. Reactivation of these latent cells can lead to the emergence of new viruses, compromising neighboring cells and establishing fresh latent reservoirs. CRISPR-Cas9 offers a distinctive approach to address this challenge, relying on a shock and kill therapy that triggers the elimination of latent reservoirs. This approach, which diverges from traditional methods, harnesses the power of sequence specificity intrinsic to CRISPR-Cas9, thereby offering potential advantages in terms of efficacy and safety [4, 8].

2.3. Screening with CRISPR-Cas9 in the context of cancer research

Besides, high-throughput genetic screening application has commonly employed for uncovering unfamiliar gene and unravelling functional roles. Through this methodology, it becomes feasible to discern the genes accountable for specific phenotypes, thereby facilitating the exploration of potential candidates for drug target discovery [2, 4].

Within the cancer research realm, the utilization of CRISPR-Cas9 screens has introduced a transformative approach. In the case of melanoma, the CRISPR approach was harnessed to enhance the expression of long noncoding RNA transcripts, shedding light on the identification of genes responsible for conferring resistance to a BRAF inhibitor. Employing cell lines equipped with the Cas9 enzyme has shown promise in enhancing the overall effectiveness of these screening methodologies [7, 8]. To further refine these screening systems, primary cells originated from Cas9 transgenic mice have been considered, aiming to optimize the screening process. Researchers are actively engaged in developing a CRISPR sgRNA library, drawing from knockout (KO) mice, which holds potential for enhanced genetic screening [8, 10].

A notable study employed a pooled CRISPR screening technique to produce dendritic cells derived from the bone marrow of Cas9 mice. Subsequent screening efforts focused on identifying regulatory factors linked to the innate immune system that are involved in the host's reaction to pathogens. It is essential to highlight that the effectiveness of CRISPR/Cas9 is heavily contingent upon the precision of target site selection [2, 5]. The application of CRISPR-based screenings has also played a pivotal role in discerning known oncogene dependencies. For instance, in myelogenous leukemia cells (KBM7 cell line), the lethal hits encompass the ABL and breakpoint cluster region (BCR), which harbor an ABL-BCR translocation. However, lethal hits in colorectal cancer cells (DLD-1 and HCT116 cell lines) involve kirsten rat sarcoma virus (KRAS) and the catalytic subunit alpha of phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA) [5, 10].



Figure 2. Categories of CRISPR-Cas9 screening methodologies employed in the realm of cancer research.

Moreover, a study conducted in A375 cells through CRISPR activation (CRISPRa) demonstrated that evasion of BRAF inhibitor-induced inhibition could be achieved by increase the expression of genes that reactivating the mitogen-activated protein kinase pathway (MAPK) [1]. As a result, the CRISPR/Cas9 approach emerges as a useful tool for generating isogenic cancer cell lines characterized by precisely combinatorial and defined genetic lesions [7]. This capacity to engineer cancer cell lines with specific genetic alterations underscores the potential for advancing our understanding of cancer biology and therapeutic responses. Figure.2 visually represents the diverse types of CRISPR/Cas9 screens employed within the realm of cancer research, further highlighting the dynamic nature of these investigative methodologies in elucidating critical aspects of cancer development and treatment strategies [7, 8].

3. Advancement in Target efficiency

3.1. Methods for Detecting Off-Target Effects in CRISPR-Cas9 Genome Editing

The Cas9-sgRNA complex is a potent genome-editing tool, capable of initiating DNA double-strand breaks through two pathways: homology-directed repair (HDR) for precise edits, albeit with inefficiency, and non-homologous end joining (NHEJ) for faster but error-prone repairs that may result in gene silencing. CRISPR/Cas9's primary challenge lies in its off-target effects, where Cas9 inadvertently cleaves unintended genomic sites due to sgRNA mismatches [3]. While in silico tools can predict off-target sites, they require experimental validation. A range of experimental methods, both and cell-based and cell-free, provide direct assessments of these off-target effects [6]. This review will delve into these techniques, highlighting their respective advantages and limitations.

3.1.1. In Silico Prediction

In silico tools predict off-target effects based on sgRNA sequences, with output biased toward sgRNA-dependent effects. Tools like CasOT, Cas-OFFinder, FlashFry, and Crisflash align sgRNAs to potential off-target sites [3, 10]. Algorithms like MIT score, CCTop, CROP-IT, CFD, DeepCRISPR, and Elevation use scoring models for computational off-target site predictions. However, these methods often lack consideration of complex intranuclear factors like epigenetics, necessitating experimental validation [6].

3.1.2. Experimental Detection:

Cell-Free Methods:

Cell-free methods, including DIG-seq, SITE-seq, Extru-seq and Digenome-seq, and CIRCLE-seq, reconstitute nuclease reactions on extracted DNA or chromatin [3]. Digenome-seq identifies indels with high sensitivity but requires high sequencing coverage. DIG-seq employs cell-free chromatin for higher accuracy. Extru-seq mechanically lyses cells before sequencing, reducing false positives. SITE-seq biotinylates cleaved sites for enrichment and requires less sequencing coverage. CIRCLE-seq enriches circularized DNA fragments for sequencing [6, 11].

Cell Culture-Based Methods:

Direct assessments in cells are more accurate due to intranuclear context influence. WGS, Cas9 ChIP–seq, IDLVs, GUIDE-seq, LAM-HTGTS, BLESS, and BLISS are used. WGS compares genome sequences before and after editing but can be costly for low-frequency off-target sites [6, 11]. Cas9 ChIP–seq identifies Cas9 binding sites, though non-specific binding is a limitation. IDLVs and GUIDE-seq measure DNA insertion during NHEJ, with GUIDE-seq being more sensitive. LAM-HTGTS detects chromosome rearrangements, while BLESS and BLISS directly label DSBs. BLISS improves sensitivity and accuracy over BLESS [3].

3.1.3. In Vivo Detection:

Discover-seq and GUIDE-tag are used for in vivo detection. Discover-seq employs MRE11 binding to detect DSBs, while GUIDE-tag enhances dsODN capture efficiency. Discover-seq is less sensitive than GUIDE-tag, capturing known and additional off-target sites [3].

Overall, off-target effects present obstacles in editing CRISPR-Cas9 genome. And the In silico prediction tools offer insights but require experimental validation. Experimental methods, both cell-based and cell-free, enable direct off-target assessment. In vivo methods like Discover-seq and GUIDE-tag provide insights into off-target effects in living organisms. Combining these approaches can enhance our understanding of off-target effects, improving the safety and precision in CRISPR-Cas9 applications for gene therapy and beyond [6, 11].

3.2. Strategies for Enhancing CRISPR/Cas9 Genome Editing Fidelity

The revolutionary CRISPR-Cas9 technique has enabled accurate genome modifications in various organisms. However, its widespread application has been limited by the potential off-target effects, where unexpected DNA editing occur at the site that resembles intended target sequence [3, 4]. These off-target effects can cause unexpected consequences and compromise the specificity of the editing process [6]. This essay will explore four developed strategies that used to reduce off-target effects and enhance the fidelity of genome editing.

3.2.1. Cas9 Protein Engineering:

Cas9, the enzyme responsible for creating DSBs at target site, is a pivotal component in system. Researchers have concentrated on improving its specificity through rational engineering approaches. One approach involves designing Cas9 mutants with enhanced fidelity like the enhanced SpCas9-HF1 (high-fidelity variant #1) and SpCas9 (eSpCas9), which have reduced binding to non-target DNA strands [3, 9, 10]. Furthermore, a hyper-precise version of Cas9, known as hypaCas9, was engineered, displaying elevated on-target effectiveness and markedly diminished off-target consequences when compared to the conventional wild-type Cas9 [11]. Unbiased high-throughput screens also identified variants like evoCas9, which exhibit superior fidelity while maintaining reasonable on-target activity. Paired Cas9 nickases, which induce single-strand breaks instead of DSBs, have been explored to minimize off-target effects. These strategies collectively enhance the precision of genome editing by minimizing unintended DNA modifications [10].

3.2.2. sgRNA Engineering

The single guide RNA (sgRNA) directs Cas9 to the intended location through complementary base-pairing. Optimizing sgRNA sequences is crucial for enhancing on-target specificity. Scientists have discovered that extending or truncating sgRNAs can influence their interaction with target DNA and off-target binding [3, 4]. Additionally, chemical modifications of sgRNAs, such as incorporation of bridged nucleic acids (2',4'-BNANC [N-Me]), 2'-O-methyl-3'-phosphonoacetate (MP), or locked nucleic acids (LNA), can reduce off-target effects. These modifications alter the kinetics of Cas9 nuclease reactivity, consequently enhancing the editing precision [10, 11].

3.2.3. DSB-Independent Gene Editing

Off-target effects primarily result from the generation of DSBs. To circumvent this, researchers have developed DSB-independent gene editing tools. Base editors, involving cytosine base editors (CBE) and adenine base editors (ABE), allow precise conversion of single nucleotides without creating DSBs. While these editors significantly reduce classical off-target effects, they introduce new forms of off-target effects, for example sgRNA-independent DNA editing and RNA editing [3,9]. Techniques like EndoV-seq and Detect-seq have developed to trace or analyze these off-target effects more accurately [4,5].

3.2.4. Delivery Method Improvement:

The delivery method of Cas9 and sgRNA into target cells significantly influences editing outcomes. Transient expression is preferred to avoid prolonged exposure and potential off-target effects. Delivery methods such as ribonucleoprotein (RNP) electroporation and lipid nanoparticle (LNP) transfection enable transient peak expression, followed by rapid turnover of editing components [6, 10]. In contrast, adeno-associated virus (AAV) vectors, which offer long-term expression, can accumulate off-target mutations over time. LNP vectors are currently favored for in vivo gene editing due to their transient expression profile, which enhances specificity [3, 11].

Overall, the continuous development of CRISPR-Cas9 genome editing strategies has led to significant advancements in reducing off-target effects and enhancing editing fidelity. Through protein and sgRNA engineering, DSB-independent editing, and improved delivery methods, scientists are working towards achieving precise and specific genome modifications [3-4, 9]. As these strategies are refined and further research is conducted, the prospect of CRISPR/Cas9 as a revolutionary technique for accurate genetic alteration is becoming progressively encouraging [5, 6].

4. Conclusion

The advent of this system has inaugurated a new epoch in genetic editing with vast implications for both therapeutic interventions and drug discovery. This technology's efficiency, precision, and programmability have enabled scientists to unravel intricate genetic pathways and identify potential drug targets with unprecedented accuracy. However, amidst its transformative potential, the spectre of off-target effects has cast a shadow over its applications, demanding comprehensive strategies to mitigate the unintended editing consequences.

Within the drug discovery realm, CRISPR/Cas9's impact is far-reaching. Its ability to generate disease-specific models and systematically manipulate genes has expedited the detection of therapeutic targets and facilitated the advancement of novel treatment approaches. Through CRISPR/Cas9 screens, researchers have dissected complex disease pathways, revealing critical insights into cancer progression and drug resistance mechanisms. The technology's power to engineer isogenic cancer cell lines equipped with specific genetic alterations has revolutionized the understanding of oncogene dependencies and therapeutic responses. In the context of antimicrobial, antiviral, and AIDS research, CRISPR-Cas9 has developed into a potential solution to combat the challenges posed by antibiotic resistance, viral infections, and latent viral reservoirs. By leveraging its sequence-specificity and gene-editing capabilities, CRISPR/Cas9 offers innovative strategies to address these pressing global health concerns.

Yet, the promise of CRISPR/Cas9 is intertwined with concerns over off-target effects. Advances in methods for detecting these effects, such as in silico prediction tools and experimental techniques, have provided essential insights into the precision and safety during genetic editing. Additionally, strategies to improve editing fidelity have emerged, ranging from Cas9 protein engineering to DSB-independent gene editing techniques. These approaches collectively seek to minimize off-target effects and optimize the precision of gene editing.

In the discourse of whether CRISPR/Cas9 truly elevates target efficiency and revolutionizes drug discovery, a balanced perspective emerges. The technology's potential is undeniable, evidenced by its transformative impact on disease modeling, target identification, and therapeutic intervention. Yet, the challenge of off-target effects remains a critical consideration, warranting ongoing research and refinement of strategies to enhance specificity. The future of CRISPR/Cas9 lies in the continual pursuit of refining its methods, optimizing its precision, and harnessing its potential to drive therapeutic breakthroughs and reshape the landscape of drug discovery. Through a dynamic interplay of innovation and careful evaluation, CRISPR/Cas9 is positioned to enhance target effectiveness and lead the path toward a novel era of precision medicine.

References

[1] Andrew Scott. A CRISPR path to drug discovery. NATURE. 2018, 555.

[2] Khurana, A., Sayed, N., Singh, V., Khurana, I., Allawadhi, P., Rawat, P. S., Navik, U., Pasumarthi, S. K., Bharani, K. K., & Weiskirchen, R. A comprehensive overview of CRISPR/Cas 9 technology and application thereof in drug discovery. Journal of Cellular Biochemistry, 2022, 123 (10), 1674 – 1698.

[3] Guo, C., Ma, X., Gao, F., & Guo, Y. Off-target effects in CRISPR/Cas9 gene editing. Frontiers in Bioengineering and Biotechnology, 11.

[4] Sherkatghanad, Z., Abdar, M., Charlier, J., & Makarenkov, V. Using traditional machine learning and deep learning methods for on- and off-target prediction in CRISPR/Cas9: a review. Briefings in Bioinformatics, 2023, 24 (3).

[5] Hendriks, D., Clevers, H., & Artegiani, B. CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids. Cell Stem Cell, 2020, 27 (5), 705 – 731.

[6] Zhang, S., Li, X., Lin, Q., & Wong, K. C. Synergizing CRISPR/Cas9 off-target predictions for ensemble insights and practical applications. Bioinformatics, 2018, 35 (7), 1108 – 1115.

[7] Bikard, D., & Barrangou, R. Using CRISPR-Cas systems as antimicrobials. Current Opinion in Microbiology, 2017, 37, 155 – 160.

[8] Yan, M. Y., Yan, H. Q., Ren, G. X., Zhao, J. P., Guo, X. P., & Sun, Y. C. CRISPR-Cas12a-Assisted Recombineering in Bacteria. Applied and Environmental Microbiology, 2017, 83 (17).

[9] Kim, D., Luk, K., Wolfe, S. A., & Kim, J. S. Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases. Annual Review of Biochemistry, 2019, 88 (1), 191 – 220.

[10] Wang, D., Zhang, C., Wang, B., Li, B., Wang, Q., Liu, D., Wang, H., Zhou, Y., Shi, L., Lan, F., & Wang, Y. Optimized CRISPR guide RNA design for two high-fidelity Cas9 variants by deep learning. Nature Communications, 2019, 10 (1).

[11] Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J. S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Research, 2014, 24 (6), 1012 – 1019.